News

The company said that graft rejection can cause severe injury to the transplanted organ and is a significant barrier to successful transplantation. Currently, the drug is approved in

A total of 100 patients will be enrolled in the new trial, which will include a randomized control arm and will expand on the results that were showed

The deal will explore the application of HemoShear’s platform in an undisclosed area of strategic interest. Initially, HemoShear will characterize biological mechanisms and the effects of drug candidates

The new products will be based on Nuvo’s patented Multiplexed Molecular Penetration Enhancer (MMPE) technology. As part of the deal, Nuvo will use its MMPE technology to formulate

The deal will see Medivation secure exclusive worldwide rights for the development and commercialization of these compounds. As part of the deal, Medivation will have access to OncoFusion’s

Currently, Firdapse (amifampridine phosphate or 3,4-DAP phosphate) is in Phase III development and it will be provided at no cost until sometime following approval. Patient enrollment in the

This patent will extend VistaGen’s intellectual property portfolio for pluripotent stem cell culture systems that produce human cells of the endoderm lineage, including liver, lung, pancreas, parathyroid and

YLB will be jointly managed by both partners and will be responsible for conducting clinical development of certain Biosimilars including regulatory filings and obtaining marketing authorizations in Japan.

Through this partnership, BettrLife’s mobile health software will be integrated with Viridian’s Maestro population health management platform, allowing users to interact directly with Viridian health coaches. Through integration